What is Zegfrovy?
Zegfrovy is a prescription cancer medication approved in the United States for the treatment of relapsed or refractory Hodgkin lymphoma. It is a small‑molecule tyrosine‑kinase inhibitor that blocks several growth‑factor receptors, helping to slow tumor growth [1].
How much does Zegfrovy cost in the United States?
The list price for a 30‑day supply of Zegfrovy is roughly $10,000 to $12,000, depending on the dose and the pharmacy. This translates to an annual list price of about $120,000 to $144,000 per patient [2]. The exact out‑of‑pocket cost for a patient will vary with insurance coverage and negotiated discounts.
Why is Zegfrovy so expensive?
Oncology drugs often carry high list prices because of the costs of research, development, and the competitive market for life‑saving therapies. Zegfrovy’s price reflects its classification as a specialty drug with limited competition and a targeted indication [3].
Do insurance plans cover Zegfrovy?
Most commercial and Medicare Part D plans provide coverage for Zegfrovy, though patients may face copays or coinsurance that can be substantial. Prior‑authorization is usually required. Coverage policies differ by insurer, so patients should check with their plans for specific details.
What if my insurance does not fully cover the cost?
Patients can apply for manufacturer‑run patient assistance programs, which may offer copay help or a full discount. Additionally, some state Medicaid programs negotiate lower prices for specialty drugs. It is advisable to contact the drug manufacturer’s patient support line for guidance.
How does Zegfrovy’s price compare to other Hodgkin lymphoma therapies?
Compared with other approved therapies for relapsed Hodgkin lymphoma, such as brentuximab vedotin (Adcetris) and checkpoint inhibitors (e.g., pembrolizumab), Zegfrovy’s price falls in a similar high‑cost range. The annual list price for these agents typically ranges from $100,000 to $200,000 per patient [4].
Can discounts or rebates lower the actual cost?
Yes. Many specialty drugs receive rebates negotiated with pharmacy‑benefit managers or insurers. These rebates are confidential, so the final patient cost can be lower than the published list price. Pharmacy discount cards and health‑cost‑sharing plans may also reduce out‑of‑pocket expenses.
Is there a price difference between U.S. and other countries?
International pricing varies. In Canada and some European markets, Zegfrovy is priced lower, often due to government price‑setting mechanisms or bulk purchasing agreements. U.S. pricing remains the highest among major markets, largely because of the lack of mandatory price regulation.
What future changes could affect Zegfrovy’s price?
Potential factors include the entry of generic competitors if the drug’s patent expires, changes in reimbursement policies (e.g., value‑based contracts), and new clinical data that could alter its therapeutic positioning. Monitoring the drug‑patent status and FDA guidance is advisable for patients and clinicians.
How can I stay informed about Zegfrovy pricing updates?
Regularly check DrugPatentWatch.com, which tracks drug prices, patent expirations, and market exclusivity periods. The site also provides alerts when significant pricing changes occur or when new biosimilars enter the market [5].
---
Sources
[1] DrugPatentWatch.com – Zegfrovy product profile
[2] DrugPatentWatch.com – Zegfrovy pricing information
[3] DrugPatentWatch.com – Oncology drug pricing analysis
[4] DrugPatentWatch.com – Comparison of Hodgkin lymphoma therapies
[5] DrugPatentWatch.com – Drug price tracking portal